

Kathryn R Wagner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11901065/publications.pdf>

Version: 2024-02-01

91
papers

7,440
citations

87723

38
h-index

56606

83
g-index

95
all docs

95
docs citations

95
times ranked

8369
citing authors

#	ARTICLE	IF	CITATIONS
1	A Combined Prospective and Retrospective Comparison of Long-Term Functional Outcomes Suggests Delayed Loss of Ambulation and Pulmonary Decline with Long-Term Eteplirsen Treatment. <i>Journal of Neuromuscular Diseases</i> , 2022, 9, 39-52.	1.1	24
2	Home-based gait analysis as an exploratory endpoint during a multicenter phase 1 trial in limb girdle muscular dystrophy type 2 and facioscapulohumeral muscular dystrophy. <i>Muscle and Nerve</i> , 2022, 65, 237-242.	1.0	8
3	iMyoblasts for ex vivo and in vivo investigations of human myogenesis and disease modeling. <i>ELife</i> , 2022, 11, .	2.8	13
4	Loss of TDP-43 function and rimmed vacuoles persist after T cell depletion in a xenograft model of sporadic inclusion body myositis. <i>Science Translational Medicine</i> , 2022, 14, eabi9196.	5.8	27
5	Human pluripotent stem cell-derived myogenic progenitors undergo maturation to quiescent satellite cells upon engraftment. <i>Cell Stem Cell</i> , 2022, 29, 610-619.e5.	5.2	10
6	Quantitative magnetic resonance imaging measures as biomarkers of disease progression in boys with Duchenne muscular dystrophy: a phase 2 trial of domagrozumab. <i>Journal of Neurology</i> , 2022, 269, 4421-4435.	1.8	6
7	Randomized phase 2 study of ACE2, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy. <i>Muscle and Nerve</i> , 2022, 66, 50-62.	1.0	8
8	Quantitative Muscle Analysis in Facioscapulohumeral Muscular Dystrophy Using Whole-Body Fat-Referenced MRI : Protocol Development, Multicenter Feasibility, and Repeatability. <i>Muscle and Nerve</i> , 2022, , .	1.0	1
9	A phase Ib/IIa, open-label, multiple ascending-dose trial of domagrozumab in fukutin-related protein limb-girdle muscular dystrophy. <i>Muscle and Nerve</i> , 2021, 64, 172-179.	1.0	5
10	CaMKII oxidation is a critical performance/disease trade-off acquired at the dawn of vertebrate evolution. <i>Nature Communications</i> , 2021, 12, 3175.	5.8	19
11	Human muscle stem cells are refractory to aging. <i>Aging Cell</i> , 2021, 20, e13411.	3.0	18
12	Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial. <i>Journal of Neuromuscular Diseases</i> , 2021, 8, 989-1001.	1.1	50
13	A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients with Duchenne Muscular Dystrophy: Results of the PolarisDMD Trial. <i>Journal of Neuromuscular Diseases</i> , 2021, 8, 769-784.	1.1	13
14	Safety and disease monitoring biomarkers in Duchenne muscular dystrophy: results from a Phase II trial. <i>Biomarkers in Medicine</i> , 2021, 15, 1389-1396.	0.6	7
15	<i>Mss51</i> deletion increases endurance and ameliorates histopathology in the <i>mdx</i> mouse model of Duchenne muscular dystrophy. <i>FASEB Journal</i> , 2021, 35, e21276.	0.2	4
16	Stem cell-based therapies for Duchenne muscular dystrophy. <i>Experimental Neurology</i> , 2020, 323, 113086.	2.0	74
17	Diabetes, metformin and cancer risk in myotonic dystrophy type I. <i>International Journal of Cancer</i> , 2020, 147, 785-792.	2.3	13
18	Improving translatability of preclinical studies for neuromuscular disorders: lessons from the TREAT-NMD Advisory Committee for Therapeutics (TACT). <i>DMM Disease Models and Mechanisms</i> , 2020, 13, .	1.2	18

#	ARTICLE	IF	CITATIONS
19	The elusive promise of myostatin inhibition for muscular dystrophy. <i>Current Opinion in Neurology</i> , 2020, 33, 621-628.	1.8	28
20	Longitudinal functional and imaging outcome measures in FKRP limb-girdle muscular dystrophy. <i>BMC Neurology</i> , 2020, 20, 196.	0.8	13
21	Engineering 3D skeletal muscle primed for neuromuscular regeneration following volumetric muscle loss. <i>Biomaterials</i> , 2020, 255, 120154.	5.7	31
22	Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy. <i>Neuromuscular Disorders</i> , 2020, 30, 492-502.	0.3	40
23	Applying genome-wide CRISPR-Cas9 screens for therapeutic discovery in facioscapulohumeral muscular dystrophy. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	44
24	The care of patients with Duchenne, Becker, and other muscular dystrophies in the COVID-19 pandemic. <i>Muscle and Nerve</i> , 2020, 62, 41-45.	1.0	54
25	A decade of optimizing drug development for rare neuromuscular disorders through TACT. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 1-2.	21.5	12
26	Duchenne muscular dystrophy hiPSC-derived myoblast drug screen identifies compounds that ameliorate disease in mdx mice. <i>JCI Insight</i> , 2020, 5, .	2.3	22
27	It's not all about muscle: fibroadipogenic progenitors contribute to facioscapulohumeral muscular dystrophy. <i>Journal of Clinical Investigation</i> , 2020, 130, 2186-2188.	3.9	3
28	AAV9 Edits Muscle Stem Cells in Normal and Dystrophic Adult Mice. <i>Molecular Therapy</i> , 2019, 27, 1568-1585.	3.7	54
29	Benign tumors in myotonic dystrophy type I target disease-related cancer sites. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 1510-1518.	1.7	16
30	The NIH Toolbox for cognitive surveillance in Duchenne muscular dystrophy. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 1696-1706.	1.7	12
31	Long-read single-molecule maps of the functional methylome. <i>Genome Research</i> , 2019, 29, 646-656.	2.4	48
32	Performing Human Skeletal Muscle Xenografts in Immunodeficient Mice. <i>Journal of Visualized Experiments</i> , 2019, , .	0.2	2
33	Identification of the hyaluronic acid pathway as a therapeutic target for facioscapulohumeral muscular dystrophy. <i>Science Advances</i> , 2019, 5, eaaw7099.	4.7	26
34	Mss51 deletion enhances muscle metabolism and glucose homeostasis in mice. <i>JCI Insight</i> , 2019, 4, .	2.3	16
35	Facioscapulohumeral Muscular Dystrophies. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2019, 25, 1662-1681.	0.4	21
36	Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. <i>Lancet Neurology</i> , The, 2018, 17, 251-267.	4.9	767

#	ARTICLE	IF	CITATIONS
37	Neurology Care, Diagnostics, and Emerging Therapies of the Patient With Duchenne Muscular Dystrophy. <i>Pediatrics</i> , 2018, 142, S5-S16.	1.0	16
38	Cardiac Management of the Patient With Duchenne Muscular Dystrophy. <i>Pediatrics</i> , 2018, 142, S72-S81.	1.0	77
39	Cancer Risk in Myotonic Dystrophy Type I: Evidence of a Role for Disease Severity. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky052.	1.4	24
40	Adipose-derived Stem/Stromal Cells on Electrospun Fibrin Microfiber Bundles Enable Moderate Muscle Reconstruction in a Volumetric Muscle Loss Model. <i>Cell Transplantation</i> , 2018, 27, 1644-1656.	1.2	35
41	Biological scaffold-mediated delivery of myostatin inhibitor promotes a regenerative immune response in an animal model of Duchenne muscular dystrophy. <i>Journal of Biological Chemistry</i> , 2018, 293, 15594-15605.	1.6	14
42	Bone health in facioscapulohumeral muscular dystrophy: A cross-sectional study. <i>Muscle and Nerve</i> , 2017, 56, 1108-1113.	1.0	6
43	Left Ventricular Dysfunction and Conduction Disturbances in Patients With Myotonic Muscular Dystrophy Type I and II. <i>JAMA Cardiology</i> , 2017, 2, 225.	3.0	25
44	Validity of the 6 minute walk test in facioscapulohumeral muscular dystrophy. <i>Muscle and Nerve</i> , 2017, 55, 333-337.	1.0	37
45	Morpholino-mediated Knockdown of DUX4 Toward Facioscapulohumeral Muscular Dystrophy Therapeutics. <i>Molecular Therapy</i> , 2016, 24, 1405-1411.	3.7	90
46	Concordant but Varied Phenotypes among Duchenne Muscular Dystrophy Patient-Specific Myoblasts Derived using a Human iPSC-Based Model. <i>Cell Reports</i> , 2016, 15, 2301-2312.	2.9	141
47	Developing a pro-regenerative biomaterial scaffold microenvironment requires T helper 2 cells. <i>Science</i> , 2016, 352, 366-370.	6.0	464
48	In Vivo Selection Yields AAV-B1 Capsid for Central Nervous System and Muscle Gene Therapy. <i>Molecular Therapy</i> , 2016, 24, 1247-1257.	3.7	98
49	Dystrophin-deficient dogs with reduced myostatin have unequal muscle growth and greater joint contractures. <i>Skeletal Muscle</i> , 2016, 6, 14.	1.9	22
50	Clinical practice considerations in facioscapulohumeral muscular dystrophy Sydney, Australia, 21 September 2015. <i>Neuromuscular Disorders</i> , 2016, 26, 462-471.	0.3	7
51	Mammalian Mss51 is a Skeletal Muscle-Specific Gene Modulating Cellular Metabolism. <i>Journal of Neuromuscular Diseases</i> , 2015, 2, 371-385.	1.1	28
52	The TREAT-NMD advisory committee for therapeutics (TACT): an innovative de-risking model to foster orphan drug development. <i>Orphanet Journal of Rare Diseases</i> , 2015, 10, 49.	1.2	21
53	Individual epigenetic status of the pathogenic D4Z4 macrosatellite correlates with disease in facioscapulohumeral muscular dystrophy. <i>Clinical Epigenetics</i> , 2015, 7, 37.	1.8	76
54	Myositis-specific autoantibodies are specific for myositis compared to genetic muscle disease. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e172.	3.1	38

#	ARTICLE	IF	CITATIONS
55	Whole-body magnetic resonance imaging evaluation of facioscapulohumeral muscular dystrophy. <i>Muscle and Nerve</i> , 2015, 52, 512-520.	1.0	63
56	Contemporary Cardiac Issues in Duchenne Muscular Dystrophy. <i>Circulation</i> , 2015, 131, 1590-1598.	1.6	240
57	Genetic disruption of Smad7 impairs skeletal muscle growth and regeneration. <i>Journal of Physiology</i> , 2015, 593, 2479-2497.	1.3	32
58	Results of a two-year pilot study of clinical outcome measures in collagen VI- and laminin alpha2-related congenital muscular dystrophies. <i>Neuromuscular Disorders</i> , 2015, 25, 43-54.	0.3	30
59	Sildenafil does not improve cardiomyopathy in <sc>D</sc>uchenne/<sc>B</sc>ecker muscular dystrophy. <i>Annals of Neurology</i> , 2014, 76, 541-549.	2.8	73
60	Human skeletal muscle xenograft as a new preclinical model for muscle disorders. <i>Human Molecular Genetics</i> , 2014, 23, 3180-3188.	1.4	48
61	Magnetic resonance imaging phenotyping of Becker muscular dystrophy. <i>Muscle and Nerve</i> , 2014, 50, 962-967.	1.0	28
62	Therapeutic advances in muscular dystrophy. <i>Annals of Neurology</i> , 2013, 74, 404-411.	2.8	70
63	Telomere position effect regulates DUX4 in human facioscapulohumeral muscular dystrophy. <i>Nature Structural and Molecular Biology</i> , 2013, 20, 671-678.	3.6	95
64	Fast skeletal muscle troponin activator in the dy2J muscular dystrophy model. <i>Muscle and Nerve</i> , 2013, 48, 279-285.	1.0	5
65	Reevaluating measures of disease progression in facioscapulohumeral muscular dystrophy. <i>Neuromuscular Disorders</i> , 2013, 23, 306-312.	0.3	41
66	Inhibiting myostatin reverses muscle fibrosis through apoptosis. <i>Journal of Cell Science</i> , 2012, 125, 3957-65.	1.2	81
67	Transcriptional profiling in facioscapulohumeral muscular dystrophy to identify candidate biomarkers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 16234-16239.	3.3	81
68	Facioscapulohumeral muscular dystrophy family studies of DUX4 expression: evidence for disease modifiers and a quantitative model of pathogenesis. <i>Human Molecular Genetics</i> , 2012, 21, 4419-4430.	1.4	150
69	A unique library of myogenic cells from facioscapulohumeral muscular dystrophy subjects and unaffected relatives: family, disease and cell function. <i>European Journal of Human Genetics</i> , 2012, 20, 404-410.	1.4	57
70	The Paradox of Muscle Hypertrophy in Muscular Dystrophy. <i>Physical Medicine and Rehabilitation Clinics of North America</i> , 2012, 23, 149-172.	0.7	85
71	Pathophysiology and Therapy of Cardiac Dysfunction in Duchenne Muscular Dystrophy. <i>American Journal of Cardiovascular Drugs</i> , 2011, 11, 287-294.	1.0	73
72	Gene expression profiling of skeletal muscles treated with a soluble activin type IIB receptor. <i>Physiological Genomics</i> , 2011, 43, 398-407.	1.0	44

#	ARTICLE	IF	CITATIONS
73	Regeneration versus fibrosis in skeletal muscle. <i>Current Opinion in Rheumatology</i> , 2011, 23, 568-573.	2.0	73
74	Clinical Applications of Myostatin Inhibitors for Neuromuscular Diseases. <i>Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry</i> , 2010, 10, 204-210.	0.5	2
75	Inhibition of myostatin does not ameliorate disease features of severe spinal muscular atrophy mice. <i>Human Molecular Genetics</i> , 2009, 18, 3145-3152.	1.4	68
76	A soluble activin type IIB receptor improves function in a mouse model of amyotrophic lateral sclerosis. <i>Experimental Neurology</i> , 2009, 217, 258-268.	2.0	75
77	The state of the field: myology. <i>Current Opinion in Neurology</i> , 2009, 22, 498-499.	1.8	0
78	A phase I/II trial of MYO-201 in adult subjects with muscular dystrophy. <i>Annals of Neurology</i> , 2008, 63, 561-571.	2.8	407
79	Approaching a New Age in Duchenne Muscular Dystrophy Treatment. <i>Neurotherapeutics</i> , 2008, 5, 583-591.	2.1	39
80	Myostatin Directly Regulates Skeletal Muscle Fibrosis. <i>Journal of Biological Chemistry</i> , 2008, 283, 19371-19378.	1.6	214
81	Myostatin does not regulate cardiac hypertrophy or fibrosis. <i>Neuromuscular Disorders</i> , 2007, 17, 290-296.	0.3	79
82	Current treatment of adult Duchenne muscular dystrophy. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2007, 1772, 229-237.	1.8	120
83	Muscle regeneration through myostatin inhibition. <i>Current Opinion in Rheumatology</i> , 2005, 17, 720-724.	2.0	50
84	Hydroxychloroquine causes severe vacuolar myopathy in a patient with chronic graft-versus-host disease. <i>American Journal of Hematology</i> , 2005, 78, 306-309.	2.0	40
85	Muscle regeneration in the prolonged absence of myostatin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 2519-2524.	3.3	181
86	Myostatin Mutation Associated with Gross Muscle Hypertrophy in a Child. <i>New England Journal of Medicine</i> , 2004, 350, 2682-2688.	13.9	1,238
87	Genetic diseases of muscle. <i>Neurologic Clinics</i> , 2002, 20, 645-678.	0.8	38
88	Loss of myostatin attenuates severity of muscular dystrophy in <i>mdx</i> mice. <i>Annals of Neurology</i> , 2002, 52, 832-836.	2.8	351
89	Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. <i>Annals of Neurology</i> , 2001, 49, 706-711.	2.8	238
90	Tyrosine and Serine Phosphorylation of Dystrophin and the 58 kDa Protein in the Postsynaptic Membrane of <i>Torpedo</i> Electric Organ. <i>Journal of Neurochemistry</i> , 1994, 62, 1947-1952.	2.1	22

#	ARTICLE	IF	CITATIONS
91	The 87K postsynaptic membrane protein from torpedo is a protein-tyrosine kinase substrate homologous to dystrophin. Neuron, 1993, 10, 511-522.	3.8	152